AEG Infrarot-Module, OmniCorder Team to Market IR Disease Detection Systems

OmniCorder Technologies Inc. (OCT; Stonybrook, NY) and AEG Infrarot-Module GmbH (AIM) entered into a strategic contract to manufacture and market infrared disease detection systems and services to the health care industry for the early detection and management of breast cancer and other diseases. As part of the agreement OmniCorder has provided a non-exclusive technology license to AIM to use OCT's proprietary digital infrared quantum well infrared photodector (QWIP) technology. AIM has provided to OCT the exclusive right to market AIM's QWIP camera for a wide array of cancer and vascular disease detection applications.

AIM's QWIP modules, based upon AIM's highly reputed hybridization, dewar, cryocooler and electronics technology have recently been developed in co-operation with the Fraunhofer Institut for Angewandte Festkoerperphysik (IAF, Freiburg, Germany) and uses patented technology from IAF.

In December 1999 OmniCorder earned FDA clearance to market its QWIP based BioScan System for applications including the adjunctive diagnosis of breast cancer and other diseases affecting the perfusion or reperfusion of blood in tissue and organs. OmniCorder owns exclusive licenses to the QWIP technology developed at NASA's Jet Propulsion Laboratory and Lockheed Martin Corp.

Edited by Kristin Keiser